Recent developments include positive clinical trial results for VCN-01, completion of enrollment in key trials, licensing of SYN-020 to Rasayana, and capital raises to support ongoing research and development.

• Theriva Biologics reported positive Phase 2b results for VCN-01 in pancreatic ductal adenocarcinoma and raised $7.5 million in a public offering to advance cancer therapeutics [N5].
• The company completed enrollment in the VIRAGE Phase 2b trial of VCN-01 and secured Fast Track and Rare Disease designations [N4].
• Theriva licensed SYN-020 to Rasayana for multiple indications, indicating a strategic partnership approach [N3].
• The company closed a $7.5 million public offering in May 2025 to support cancer therapeutics development [N6][N7][N8].
• Theriva Biologics highlighted key achievements in Q3 2024, reflecting ongoing progress in clinical and corporate milestones [N1].
• Theriva licensed SYN-020 in a recent deal reported in February 2026, expanding its pipeline reach [N2].

Theriva Biologics has advanced its lead oncolytic virus candidate VCN-01 through Phase 2b clinical trials with positive results and regulatory designations, demonstrating potential in treating metastatic pancreatic cancer. The company’s successful completion of enrollment and ongoing clinical development, combined with strategic licensing of SYN-020 to Rasayana, indicate active pipeline management and potential for future partnerships. Recent capital raises provide funding to support near-term clinical and regulatory activities. If clinical programs progress successfully and additional financing is secured, Theriva could establish a foundation for future product commercialization and growth.

Theriva Biologics faces significant risks including its history of recurring operating losses, substantial accumulated deficit, and dependence on external financing to fund operations. The company has no approved products or commercial revenue and may not generate revenue for several years, if at all. Its ability to continue as a going concern is uncertain without additional capital. Clinical development is subject to regulatory, manufacturing, and competitive risks, and failure to achieve regulatory approvals or commercial viability could impair the company’s prospects. Dilution from future equity offerings and milestone payments related to acquisitions may further strain financial resources.

Theriva Biologics’ moat is primarily based on its proprietary oncolytic virus technology platform targeting solid tumors, including its lead candidate VCN-01. The company has secured regulatory designations such as Fast Track and Rare Disease for VCN-01, which may facilitate development and potential market access. However, as a clinical-stage company without approved products or commercial infrastructure, its competitive advantage is limited by the early development stage, capital constraints, and competition from larger, well-established pharmaceutical companies with greater resources and existing marketed products. Intellectual property protections and licensing agreements contribute to its technological moat but remain subject to competitive and regulatory risks.

• Going Concern and Capital Requirements: Theriva’s financial statements include an explanatory paragraph about its ability to continue as a going concern due to recurring losses and net capital deficiency. The company depends on raising additional equity or debt financing and achieving operating efficiencies to sustain operations.
• Clinical and Regulatory Risks: The company’s product candidates are in early to mid-stage clinical development and require extensive additional evaluation and regulatory approvals before commercialization. Failure to demonstrate safety and efficacy or obtain regulatory approvals would adversely affect the business.
• Capital Raising and Dilution: Theriva has no committed financing sources and may need to raise capital through equity or debt offerings, which could dilute existing stockholders. Restrictions on securities sales and market conditions may limit capital raising options.
• Competition: The company operates in a highly competitive biotechnology and pharmaceutical industry with larger, well-established competitors that have greater resources, marketed products, and strategic partnerships.
• Manufacturing and Supply Chain: Theriva relies on third-party manufacturers and suppliers for clinical trial materials. Disruptions or inability to secure quality materials could delay clinical trials and increase costs.
• Internal Controls: The company identified material weaknesses in internal controls in prior periods but reported remediation by the end of 2024. Future control failures could impact financial reporting and investor confidence.

• Theriva Biologics, Inc. is a clinical-stage biopharmaceutical company focused on developing oncolytic viruses (OVs) for cancer treatment, specifically targeting solid tumors.
• The company began focusing on OV development in 2022 and has no products approved for commercial sale or significant revenue to date.
• Theriva's lead product candidate is VCN-01 (zabilugene almadenorepvec), which is in Phase 2b clinical trials for metastatic pancreatic ductal adenocarcinoma (mPDAC).
• The company completed enrollment in the VIRAGE Phase 2b trial of VCN-01 and secured Fast Track and Rare Disease designations for this indication.
• Theriva has reported positive Phase 2b results for VCN-01 and is conducting additional clinical studies including a potential Phase 2a study evaluating dosing frequency.
• The company has licensed SYN-020 to Rasayana for multiple indications, indicating a strategy to out-license or partner certain product candidates.
• Theriva completed a $7.5 million public offering in May 2025 to advance cancer therapeutics development.
• As of December 31, 2025, Theriva had cash and cash equivalents of approximately $13.1 million and current assets of $17.5 million, with current liabilities of about $10 million, resulting in a current ratio of 1.74 and a cash ratio of 1.59.
• The company reported an accumulated deficit of approximately $358.7 million as of December 31, 2025, reflecting significant historical losses.
• Theriva's consolidated financial statements include an explanatory paragraph regarding its ability to continue as a going concern due to recurring losses and net capital deficiency.
• The company expects its current cash to fund operations into the first quarter of 2027, covering overhead, clinical trials, manufacturing scale-up, regulatory interactions, and preclinical studies for VCN-01 and VCN-12.
• Theriva's ability to continue operations depends on obtaining additional financing, achieving operating efficiencies, reducing expenditures, and ultimately generating revenue.
• The company has no committed sources of financing currently and may need to raise capital through equity or debt offerings, licensing, or strategic partnerships.
• Theriva has experienced material weaknesses in internal controls in the past but reported effective controls as of December 31, 2025.
• The company faces risks including the need for additional capital, competition from larger pharmaceutical companies, manufacturing and supply challenges, and regulatory approval uncertainties.
• Theriva's management monitors company performance through achievement of preclinical and clinical research goals and cash allocation based on budgeted expenses.
• The company has agreed to pay up to $70.2 million in contingent consideration related to the acquisition of VCN, with $7.3 million paid and $5 million deferred pending discussions.
• Theriva's operations are managed as one operating segment focused on discovery and development of oncolytic viruses.
• The company has conducted a reverse stock split in 2024 to consolidate shares and adjust authorized shares.
• Theriva's recent business developments include licensing SYN-020 to Rasayana, completing enrollment in clinical trials, reporting positive clinical results, and raising capital through public offerings.